Lipidomics reveals potential biomarkers and pathophysiological insights in the progression of diabetic kidney disease - Guo, Xiaozhen; Zhang, Zixuan; Li, Cuina; Li, Xueling; Cao, Yutang; Wang, Yangyang; Li, Jiaqi; Wang, Yibin; Wang, Kanglong; Liu, Yameng; Xie, Cen; Zhong, Yifei (Metabolism open, 2025)
Keywords: Biomarker; Diabetes kidney disease; Diabetes mellitus; Endocrinology and Metabolism; Lipidomics; Lysophosphatidylethanolamines; Original Research Paper; FFA; PS; ALT; DM; AUC; HDL-C; LASSO; UHPLC; DKD; CKD-EPI; SCr; ROC; PLA2; Lipidomics; PKC; Aclycar; Ctrl; CVD; Cer; MAG; RF; SVM-RFE; LacCer; AMPK; LPA; LPC; ESRD; LPE; Biomarker; LDL-C; BUN; SM; UACR; HbA1c; eGFR; AST; CE; OR; Diabetes mellitus; CI; Q-TOF mass spectrometer; PLS-DA; PP2A; DAG; TC; DKD-A; PA; PC; DKD-E; PE; Lysophosphatidylethanolamines; PG; Diabetes kidney disease; PI; TAG; Cardiovascular disease; Random forest; Chronic Kidney Disease Epidemiology Collaboration; Advanced stage of DKD; Lysophosphatidylcholine; Phosphatidylinositol; Total cholesterol; Ceramide; Early stage of DKD; Lysophosphatidylethanolamine; Urinary albumin-to-creatinine ratio; High-density lipoprotein cholesterol; Free fatty acid; Quadrupole time-of-flight mass spectrometer; Estimated glomerular filtration rate; Low-density lipoprotein cholesterol; Serum creatinine; Lysophosphatidic acid; Partial least squares-discriminant analysis; Phosphatidylcholine; Sphingomyelin; Protein phosphatase 2A; Ultra performance liquid chromatography; End-stage renal disease; Lactosylceramide; Protein kinase C; Diacylglycerol; Triacylglycerol; Aspartate transaminase; Phosphatidic acid; Cholesterol ester; Phospholipase A2; Aclycarnitine; Support vector machine-recursive feature elimination; Least absolute shrinkage and selection operator; Glycosylated hemoglobin, type A1c; AMP-activated protein kinase; Receiver operating characteristic curve